News stories about Horizon Therapeutics (NASDAQ:HPTX) have been trending somewhat positive on Saturday, according to Accern. The research firm identifies positive and negative news coverage by reviewing more than 20 million news and blog sources. Accern ranks coverage of companies on a scale of negative one to one, with scores nearest to one being the most favorable. Horizon Therapeutics earned a daily sentiment score of 0.22 on Accern’s scale. Accern also assigned media coverage about the biopharmaceutical company an impact score of 45.2971721772663 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the stock’s share price in the next several days.
Horizon Therapeutics (NASDAQ HPTX) opened at 46 on Friday. Horizon Therapeutics has a 1-year low of $46.00 and a 1-year high of $46.00. The firm has a 50-day moving average of $46.00 and a 200 day moving average of $46.00.
ILLEGAL ACTIVITY NOTICE: “Horizon Therapeutics (HPTX) Given Daily News Sentiment Rating of 0.22” was published by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are reading this piece of content on another site, it was illegally stolen and republished in violation of U.S. & international copyright laws. The legal version of this piece of content can be viewed at https://www.dispatchtribunal.com/2017/10/28/horizon-therapeutics-hptx-given-daily-news-sentiment-rating-of-0-22.html.
About Horizon Therapeutics
Horizon Therapeutics, Inc, formerly Hyperion Therapeutics, Inc, is a biopharmaceutical company. The Company is engaged in the development and commercialization of therapeutics to treat disorders in the areas of orphan diseases. The Company’s products include RAVICTI (glycerol phenylbutyrate) oral liquid, BUPHENYL and AMMONAPS (sodium phenylbutyrate) tablets and powder.
Receive News & Ratings for Horizon Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Horizon Therapeutics Inc and related companies with MarketBeat.com's FREE daily email newsletter.